Effects of a newly developed fat emulsion containing eicosapentaenoic acid and docosahexaenoic acid on fatty acid profiles in rats.
A new fat emulsion of symmetrical triacylglycerols, containing only eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) was developed. The effects of this preparation on serum and liver fatty acid composition were investigated. Male Sprague-Dawley rats were fed a fat-free oral diet for 2 wk and were then divided into two groups. Seven rats were infused for 7 d with 1 mL of the new fat emulsion, which accounted for 1% of total caloric intake. The other 7 rats received saline. Both groups of rats received a fat-free diet during the infusion. EPA and DHA decreased to one third to one fifth of normal value after 2 wk on a fat-free diet. EPA and DHA of serum and liver remained at a low level in the control group throughout the study. But in the rats administered with the new fat emulsion, EPA and DHA increased rapidly and exceeded normal values in both serum and liver after 7 d of infusion. Decreased arachidonic acid with increased 20:3n-9 resulted in the rise of the triene/tetraene (T/T) ratio to greater than 0.4, indicating an n-6 essential fatty acid deficiency in the control rats. In the group administered the new fat emulsion, however, 20:3n-9 and total content of monounsaturated fatty acids decreased significantly, and the T/T ratio was less than than 0.4 in both serum and liver. In conclusion, the intravenous use of a newly developed fat emulsion containing EPA and DHA is useful in improving the EPA and DHA status of serum and liver without any harmful effects. Beneficial effects are expected in the modulation of inflammatory and stress response.
Tashiro
T
T
First Department of Surgery, Chiba Univeristy Medical School, Japan.
Yamamori
H
H
Hayashi
N
N
Sugiura
T
T
Takagi
K
K
Furukawa
K
K
Nakajima
N
N
Itoh
I
I
Wakabayashi
T
T
Ohba
S
S
Akahane
N
N
D000818:Animals; D016718:Arachidonic Acid / Q000097:blood / Q000378:metabolism; D004281:Docosahexaenoic Acids / Q000008:administration & dosage* / Q000032:analysis / Q000493:pharmacokinetics; D015118:Eicosapentaenoic Acid / Q000008:administration & dosage* / Q000032:analysis / Q000493:pharmacokinetics; D002149:Energy Intake; D005217:Fat Emulsions, Intravenous / Q000032:analysis / Q000493:pharmacokinetics / Q000494:pharmacology*; D005227:Fatty Acids / Q000097:blood / Q000378:metabolism*; D015525:Fatty Acids, Omega-3 / Q000378:metabolism; D043371:Fatty Acids, Omega-6; D005231:Fatty Acids, Unsaturated / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley
D005217:Fat Emulsions, Intravenous; D005227:Fatty Acids; D015525:Fatty Acids, Omega-3; D043371:Fatty Acids, Omega-6; D005231:Fatty Acids, Unsaturated; D004281:Docosahexaenoic Acids; D016718:Arachidonic Acid; D015118:Eicosapentaenoic Acid